Company / Operating Cash Flow
Wave Life Sciences Ltd. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$187.5M
FY2025
5-year range
-$187.5M / -$19.4M
FY2021-FY2025
Trend
-24.1%
vs FY2024
Sector context
#166 of 216
Health Care
What the data says
Wave Life Sciences Ltd.'s operating cash flow of -$187M is lower than 77% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$188M in FY2020 to -$19M in FY2023.
Based on SEC 10-K filings.
-$187M in FY2025.
Declined from -$19M to -$187M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 216This company -$187.5M Sector average $658.7M
▼
-128.5% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 24.1% year-over-year.
- Ranks #166 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$187.5M | -24.1% |
| FY2024 | -$151.0M | -677.2% |
| FY2023 | -$19.4M | +78.2% |
| FY2022 | -$89.0M | +23.3% |
| FY2021 | -$116.0M | +38.4% |
| FY2020 | -$188.2M | -125.0% |
| FY2019 | -$83.7M | -266.0% |
| FY2018 | -$22.9M | +72.7% |
| FY2017 | -$83.7M | -162.1% |
| FY2016 | -$31.9M | -799.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026